CollPlant Biotechnologies (CLGN) Goodwill & Intangibles (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Goodwill & Intangibles came in at $73000.0 in Q4 2025, down 99.94% YoY from $131.0 million in Q4 2024, and down 28.43% on a QoQ basis from $102000.0 in Q2 2025.
CollPlant Biotechnologies (CLGN) Goodwill & Intangibles (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Goodwill & Intangibles data on file, last reported at $73000.0 in Q4 2025.
- Quarterly Goodwill & Intangibles fell 99.94% year-over-year to $73000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73000.0 (down 99.94% YoY) and the FY2025 annual result came in at $73000.0, down 99.94% from the prior year.
- Goodwill & Intangibles declined to $73000.0 in Q4 2025, from $102000.0 in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $243.0 billion in Q4 2021 to a low of $73000.0 in Q4 2025.
- A 5-year average of $13.6 billion and a median of $236500.0 in 2022 frame the typical range for Goodwill & Intangibles.
- Annual changes were most pronounced in 2021 — Goodwill & Intangibles surged 296341363.41% — and 2025, when it slumped 99.94%.
- Tracing CLGN's Goodwill & Intangibles over 5 years: stood at $243.0 billion in 2021, then plunged by 99.9% to $245.0 million in 2022, then tumbled by 99.92% to $188000.0 in 2023, then surged by 69580.85% to $131.0 million in 2024, then tumbled by 99.94% to $73000.0 in 2025.
- The last three Goodwill & Intangibles figures came in at $73000.0 (Q4 2025), $102000.0 (Q2 2025), and $131.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Dec 31, 2024 | 131.00 Mn |
| Sep 30, 2024 | 145.00 Mn |
| Jun 30, 2024 | 159,000.00 |
| Mar 31, 2024 | 173.00 Mn |
| Dec 31, 2023 | 188,000.00 |
| Sep 30, 2023 | 202.00 Mn |
| Jun 30, 2023 | 216,000.00 |
| Mar 31, 2023 | 231,000.00 |
| Dec 31, 2022 | 245.00 Mn |
| Sep 30, 2022 | 238,000.00 |
| Jun 30, 2022 | 235,000.00 |
| Mar 31, 2022 | 239,000.00 |
| Dec 31, 2021 | 243.00 Bn |
| Sep 30, 2021 | 194,000.00 |
| Jun 30, 2021 | 164,000.00 |
| Mar 31, 2021 | 138.00 Mn |
| Dec 31, 2020 | 82,000.00 |
| Sep 30, 2020 | 46,000.00 |